

HepG2 cells, in which constant expression of UCP - 2 was confirmed by RT - PCR, and the activity was examined. --

### REMARKS

Applicants submit that the foregoing amendments merely correct typographical errors in the submission. Applicants respectfully request the Examiner to amend the Specification accordingly.

In addition, it has come to Applicants' attention that the previously submitted copy of U.S. Patent No. 5,849,514, was incomplete. Applicants hereby submit a complete copy.

Finally, Applicants also hereby submit copies of the Translation of the PCT International Preliminary Examination Report and the PCT Notification of Transmittal of Copies of Translation of the International Preliminary Examination Report.

In view of the foregoing amendments and remarks, the present application is respectfully considered in the condition for allowance.

An early consideration and allowance of the application are earnestly solicited.

Respectfully submitted,

Date:

September 20, 2001

Kathryn A. Piffat, Ph.D.

Kathryn A. Piffat, Ph.D., (Reg. 34,901)  
DIKE, BRONSTEIN, ROBERTS & CUSHMAN  
Intellectual Property Practice Group of  
EDWARDS & ANGELL, LLP.  
P.O. Box 9169  
Boston, MA 02209  
Telephone: (617) 439-4444  
Facsimile: (617) 439-4170

**APPENDIX I**

**REVISIONS OF THE SPECIFICATION PURSUANT TO**  
**REVISED RULE § 1.121**

**In the Specification:**

The paragraph at page 7, lines (1-3), should be replaced with the following paragraph:

-- Figure 2 shows the base sequence of cDNA containing the human UCP-2 promoter region cloned in Example 1 (continued from Figure 1 to Figure [2] 3).--

The paragraph at page 23, line 29, to page 24, line 4, should be replaced with the following paragraph:

-- EcoRI fragment (3.5 kbp) was isolated from the genomic human UCP-2 DNA and blunted using Blunting High Kit (TOYOBO Co.), and then ligated to SmaI-digested pGL3-Basic plasmid DNA. Following the above procedure, human UCP-2 promoter/luciferase vector ([pGL-3UCP2]pGL3-UCP2) was constructed in which the base number 1 - 3505 shown in Figures 1 to 6 was inserted into pGL3-Basic vector. The constructed human UCP-2 promoter/luciferase vector was temporarily transfected in HepG2 cells, in which constant expression of UCP-2 was confirmed by RT-PCR, and the activity was examined. --

09/869098

JC03 Rec'd PCT/PTO 21 JUN 2001

Docket No. 46432/56000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Yukio TOYODA, *et al.*

EXAMINER: N/A

SERIAL NO. N/A

GROUP: N/A


FILED: HERewith

FOR:

ASSISTANT COMMISSIONER OF PATENTS  
WASHINGTON, D.C. 20231

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as Express Mail in an envelope addressed to BOX PATENT APPLICATION Assistant Commissioner for Patents, Washington, D.C. 20231 on JUNE 21, 2001.

  
Judith A. Herrick

STATEMENT REGARDING SEQUENCE LISTING


Applicant hereby submits a diskette containing a machine-readable copy of the Sequence Listing.

The contents of the Sequence Listing diskette submitted herewith are the same as the contents of the paper form of the Sequence Listing submitted herewith. The sequences on the diskette and on the paper listing are identical to the sequences submitted in the application as filed.

Please charge our deposit account 04-1105 for any deficiencies.

Respectfully submitted,

Date: June 21, 2001



David G. Conlin, (Reg. No. 27,026)  
Kathryn A. Piffat, Ph.D., (Reg. No. 34,901)  
Dike, Bronstein, Roberts & Cushman, LLP  
Intellectual Property Practice Group  
EDWARDS & ANGELL, LLP  
P.O. Box 9169  
Boston, Massachusetts 02209  
617-439-4444

09869098-092001